About us Contacts Drug interactions: 390 212
Drug search by name

Mycobutin and Vitekta

Determining the interaction of Mycobutin and Vitekta and the possibility of their joint administration.

Check result:
Mycobutin <> Vitekta
Relevance: 07.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using elvitegravir together with rifabutin is not recommended. Combining these medications may significantly decrease the blood levels of elvitegravir, which may reduce its effectiveness in treating HIV infection. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with rifabutin may significantly decrease the plasma concentrations of elvitegravir. The mechanism involves rifabutin induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of elvitegravir. When rifabutin 150 mg once every other day was given with elvitegravir 150 mg plus cobicistat 150 mg once a day to 12 study subjects, elvitegravir mean peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) decreased by approximately 9%, 21% and 67%, respectively. At the same time, the mean Cmax, AUC and Cmin of 25-O-desacetylrifabutin, the active metabolite of rifabutin, increased by 4.84-, 6.25- and 4.94-fold, respectively, compared to administration of rifabutin 300 mg once daily. High plasma levels of 25-O-desacetylrifabutin is associated with toxicities including leucopenia, uveitis, arthralgias, and skin discoloration.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with rifabutin should generally be avoided.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • "Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov)." Gilead Sciences, Foster City, CA.
Mycobutin

Generic Name: rifabutin

Brand name: Mycobutin

Synonyms: n.a.

Vitekta

Generic Name: elvitegravir

Brand name: Vitekta

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction